



(12) Translation of
European patent specification

(11) NO/EP 3433234 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 231/12 (2006.01) C07D 263/32 (2006.01) C07D 413/04 (2006.01)
C07D 233/64 (2006.01) C07D 271/06 (2006.01) C07D 413/06 (2006.01)
C07D 249/06 (2006.01) C07D 277/26 (2006.01) C07D 413/10 (2006.01)
C07D 249/08 (2006.01) C07D 285/08 (2006.01) C07D 417/04 (2006.01)
C07D 261/08 (2006.01) C07D 285/12 (2006.01) C07D 495/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.02.14
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.10.27
(86)	European Application Nr.	17714623.0
(86)	European Filing Date	2017.03.20
(87)	The European Application's Publication Date	2019.01.30
(30)	Priority	2016.03.22, US, 201662311888 P 2016.08.02, US, 201662369778 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA ; MD
(73)	Proprietor	Merck Sharp & Dohme Corp., 126 East Lincoln Avenue, Rahway, NJ 07065-0907, USA
(72)	Inventor	CROWLEY, Brendan, M., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA CAMPBELL, Brian, T., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA DUFFY, Joseph, L., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, USA GRESHOCK, Thomas, J., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA GUIADEEN, Deodial, G., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA HARVEY, Andrew John, 4A/6 Ranley Grove, Paddington, New South Wales QLD4064, Australia HUFF, Belinda, C., 85 Morphett Road, Camden Park, South Australia 5038, Australia LEAVITT, Kenneth, J., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA RADA, Vanessa, L., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA SANDERS, John, M., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA SHIPE, William, D., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA SUEN, Linda, M., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA BELL, Ian, M., 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS**

(56) References
Cited: WO-A1-2015/191799, WO-A1-2014/019023, WO-A1-2013/005153


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

3433234

1


Patentkrav

1. Forbindelse med formelen I:



eller et farmasøytisk akseptabelt salt derav, hvor:

X er valgt fra



Y er 4 substituenten, hver uavhengig valgt fra H, (C₁-C₄)alkyl, halogen og OH, hvor alkylet eventuelt er substituert med ett eller flere halogen eller OH;

A er en 5-leddet heteroarylling som er substituert med 1 til 3 R-grupper, hver uavhengig valgt fra OH, okso, NR⁷R⁸, CN, (C₁-C₁₂)alkoksy, halogen, amino(C₁-C₁₂)alkyl, hydroksy(C₁-C₁₂)alkyl, (C₁-C₁₂)alkyl, (C₃-C₁₀)sykloalkyl, aryl, heteroaryl med 5-14-leddede ringatomer og inneholdende fra 1 til 4

heteroatomer valgt fra O, N og S, og heterosyklil med 3-10-leddede ringatomer inneholdende fra 1 til 4 heteroatomer valgt fra O, N og S, hvor nevnte (C₁-C₁₂)alkoksy, amino(C₁-C₁₂)alkyl, hydroksy(C₁-C₁₂)alkyl, (C₁-C₁₂)alkyl, (C₃-C₁₀)sykloalkyl, aryl, heteroaryl med 5-14-leddede ringatomer og inneholdende

fra 1 til 4 heteroatomer valgt fra O, N og S og heterosyklil med 3-10-leddede ringatomer inneholdende fra 1 til 4 heteroatomer valgt fra O, N og S eventuelt er substituert med én eller flere substituenten uavhengig valgt fra F, Cl, Br, OH, okso, CF₃, OCF₃, CN, (C₁-C₆)alkyl, O(C₁-C₄)alkyl, S(C₁-C₄)alkyl, C=O(C₁-C₄)alkyl, (C=O)NR⁷R⁸, (C=O)OR⁷, (C₂-C₄)alkynyl, (C₃-C₆)sykloalkyl, O(C₃-C₆)sykloalkyl, C=O(C₃-C₆)sykloalkyl, aryl, heteroaryl og heterosyklil, hvor nevnte alkyl, aryl, heteroaryl og heterosyklil eventuelt uavhengig er substituert med ett eller flere halogen, CF₃, OH og okso;

3433234

2

R^1 er H eller (C_1-C_4) alkyl;

R^2 er H eller (C_1-C_4) alkyl;

R^3 er H, halogen eller (C_1-C_4) alkyl, hvor alkylet eventuelt er substituert med ett eller flere halogen;

5 R^4 er H, halogen eller (C_1-C_4) alkyl, hvor alkylet eventuelt er substituert med ett eller flere halogen;

eller R^3 og R^4 eventuelt kan komme til sammen for å danne en syklopropyl-, syklobutyl-, syklopentyl- eller sykloheksylring hvor ringen eventuelt kan være substituert med én eller flere substituerter uavhengig valgt fra OH, halogen, eller (C_1-C_4) alkyl;

10

R^5 er H eller (C_1-C_4) alkyl;

R^6 er H eller (C_1-C_4) alkyl;


R^7 er H eller (C_1-C_4) alkyl;

R^8 er H eller (C_1-C_4) alkyl; og

15

R^a er H eller (C_1-C_4) alkyl.

2. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav,




hvor X er

20

3. Forbindelse ifølge et hvilket som helst av kravene 1- 2, eller et farmasøytisk akseptabelt salt derav, hvor Y er H.

4. Forbindelse ifølge et hvilket som helst av kravene 1- 3, eller et farmasøytisk akseptabelt salt derav, hvor A er valgt fra

25



hver substituert med 1 til 3 R-grupper uavhengig valgt fra (C₁-C₄)alkyl, (C₃-C₆)sykloalkyl, aryl, heteroaryl og heterosyklyl, hvor hver eventuelt er substituert med én eller flere substituenten uavhengig valgt fra F, Cl, Br, OH, okso, CF₃, OCF₃, CN, (C₁-C₄)alkyl, O(C₁-C₄)alkyl, S(C₁-C₄)alkyl, C=O(C₁-C₄)alkyl, (C₂-C₄)alkynyl, (C₃-C₆)sykloalkyl, O(C₃-C₆)sykloalkyl, C=O(C₃-C₆)sykloalkyl, aryl, heteroaryl og heterosyklyl, hvor nevnte alkyl, aryl, heteroaryl og heterosyklyl eventuelt uavhengig er substituert med ett eller flere F, Cl, CF₃, OH og okso.


5. Forbindelse ifølge et hvilket som helst av kravene 1- 4, eller et farmasøytisk akseptabelt salt derav, hvor R⁵ og R⁶ uavhengig er H eller metyl.

6. Forbindelse ifølge et hvilket som helst av kravene 1- 5, eller et farmasøytisk akseptabelt salt derav, hvor R³ og R⁴ uavhengig er H, F eller metyl.

7. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, med formelen:

3433234


4



hvor;

5

A er valgt fra



hver substituert med 1 til 2 R-grupper uavhengig valgt fra (C₁-C₄)alkyl, (C₃-C₆)sykloalkyl, aryl, heteroaryl og heterosykl, hvor hver eventuelt er substituert med én eller flere substituerter uavhengig valgt fra F, Cl, Br, OH, okso, CF₃, OCF₃, CN, (C₁-C₄)alkyl, O(C₁-C₄)alkyl, S(C₁-C₄)alkyl, C=O(C₁-C₄)alkyl, (C₂-C₄)alkynyl, (C₃-C₆)sykloalkyl, O(C₃-C₆)sykloalkyl, C=O(C₃-C₆)sykloalkyl, aryl, heteroaryl og heterosykl, hvor nevnte alkyl, aryl, heteroaryl og heterosykl eventuelt uavhengig er substituert med ett eller flere F, Cl, CF₃, OH og okso;


R³ og R⁴ uavhengig er H, F eller metyl; og

R⁵ og R⁶ uavhengig er H eller metyl.

3433234

5


8. Forbindelse ifølge krav 7, eller et farmasøytisk akseptabelt salt derav, med formelen:



5

hvor;

A er valgt fra



10

hver substituert med 1 til 2 R-grupper uavhengig valgt fra (C₁-C₄)alkyl, (C₃-C₆)sykloalkyl, fenyl, indanyl, piperidiny, pyridiny, furanyl, oksazolyl, benzoksaziny, syklopentalpyrroly, tienopyrroly, tiazolyl, imidazolyl, azetidiny, pyrroly, pyraziny, kinoliny og benzotiazolyl, hvor hver eventuelt er substituert med én eller flere substituerter uavhengig valgt fra F, Cl, Br, OH, okso, CF₃, OCF₃, CN, (C₁-C₄)alkyl, O(C₁-C₄)alkyl, S(C₁-C₄)alkyl, C=O(C₁-C₄)alkyl, (C₂-C₄)alkynyl, (C₃-C₆)sykloalkyl, O(C₃-C₆)sykloalkyl, C=O(C₃-C₆)sykloalkyl, fenyl, O-fenyl, imidazolyl, pyraziny, furanyl, oksazolidiny, pyrrolidiny og benzoksazolyl, hvor nevnte alkyl, fenyl, oksazolidiny, pyrrolidiny og benzoksazolyl eventuelt uavhengig er substituert med én eller flere F, Cl, CF₃ og okso; og

20

R³ og R⁴ uavhengig er H, F eller metyl; og


R⁵ og R⁶ uavhengig er H eller metyl.

9. Forbindelse ifølge krav 1 med formelen:

25

3433234

6



eller et farmasøytisk akseptabelt salt derav, hvor;

R er valgt fra (C₁-C₄)alkyl, (C₃-C₆)sykloalkyl, fenyl, indanyl, piperidiny, pyridiny, furanyl, oksazolyl, benzoksaziny, syklopentalpyrroly, tienopyrroly, tiazolyl, imidazolyl, azetidiny, pyrroly, pyraziny, kinoliny og benzotiazolyl, hvor hver eventuelt er substituert med én eller flere substituerter uavhengig valgt fra F, Cl, Br, OH, okso, CF₃, OCF₃, CN, (C₁-C₄)alkyl, O(C₁-C₄)alkyl, S(C₁-C₄)alkyl, C=O(C₁-C₄)alkyl, (C₂-C₄)alkynyl, (C₃-C₆)sykloalkyl, O(C₃-C₆)sykloalkyl, C=O(C₃-C₆)sykloalkyl, fenyl, O-fenyl, imidazolyl, pyraziny, furanyl, oksazolidiny, pyrrolidiny og benzoksazolyl, hvor nevnte alkyl, fenyl, oksazolidiny, pyrrolidiny, og benzoksazolyl eventuelt uavhengig er substituert med ett eller flere F, Cl, CF₃ og okso;

R³ og R⁴ uavhengig er H, F eller metyl; og

R⁵ og R⁶ uavhengig er H eller metyl.

10. Forbindelse ifølge ethvert foregående krav som er valgt fra gruppen bestående av

4-((1S,3S)-3-(3-(5-Fluor-2-metylphenyl)-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl)-bensensulfonamid;

4-((1S,3S)-3-(5-(2-Syklopropyletyl)-1,2,4-oksadiazol-3-yl)-2,2-dimetylsyklopropyl)bensensulfonamid;

4-((1S,3S)-2,2-Dimetyl-3-(5-(2,3,6-trifluorphenyl)-1,2,4-oksadiazol-3-yl)syklopropyl) bensensulfonamid;

4-((1R,2R)-2-(3-(3-Fluorphenyl)-1,2,4-oksadiazol-5-yl)syklopropyl)bensensulfonamid;

4-{(1R,3R)-3-[5-(2,4-Difluorphenyl)-1,3,4-tiadiazol-2-yl]-2,2-dimetylsyklopropyl} bensensulfonamid;

4-{(1S,3S)-3-[5-(2,4-Difluorphenyl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} bensensulfonamid;

- 4- {(1*S*,3*S*)-2,2-Difluor-3-[3-(propan-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(5-Fenyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(4-Fenyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 5 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(2-fenyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(3-fenylisoksazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(1-fenyl-1*H*-1,2,3-triazol-4-yl)syklopropyl]benzensulfonamid;
- 10 4- {(1*R*,3*R*)-3-[1-(3-Fluorfenyl)-1*H*-pyrazol-4-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[4-(3-Fluorfenyl)-1,3-tiazol-2-yl]syklopropyl}benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(5-Metyl-4-fenyl-1,3-tiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(4-Metyl-5-fenyl-1,3-tiazol-2-yl)syklopropyl]benzensulfonamid;
- 15 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(5-fenyl-1,3-tiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-*trans*-2-[3-(Propan-2-yl)-1,2,4-tiadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 20 4-((1*R*,3*R*)-3-(3-Sykloheksyl-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl)benzensulfonamid; 4- {(1*S*,3*S*)-2,2-Dimetyl-3-[5-(propan-2-yl)-1,3-tiazol-2-yl]syklopropyl}benzensulfonamid;
- 4-(2-Metyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl)benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[1-(3-Fluorbenzyl)-1*H*-pyrazol-3-yl]syklopropyl}benzensulfonamid;
- 25 4-*trans*-2-(2-Fenyl-1,3-oksazol-4-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(2-Fenyl-1,3-tiazol-4-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[1-(3-Fluorfenyl)-1*H*-1,2,3-triazol-4-yl]syklopropyl}benzensulfonamid;
- 30 4-[(1*R*,2*R*)-2-(2-Fenyl-1,3-tiazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(2-Sykloheksyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[5-(Piperidin-1-yl)-1,2,4-tiadiazol-3-yl]syklopropyl}benzensulfonamid;
- 4-*trans*-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]fenylsulfamat;
- 35

- 4-[(1*R*,3*R*)-3-(4,5-Disyklopropyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[*trans*-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]-2-fluorbenzensulfonamid;
- 5 5-[*trans*-2,2-Dimetyl-3-[4-(metylsulfonyl)fenyl]syklopropyl]-3-fenyl-1,2,4-oksadiazol;
- 4-[*trans*-3-(5-Syklopentylisoksazol-3-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-[2-(3-Fluorfenyl)-1-metyl-1*H*-imidazol-4-yl]-2,2-dimetylsyklopropyl] benzensulfonamid;
- 10 4-[(*trans*-2,2-Diklor-3-[3-(3-fluorfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl) benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[5-(Piperidin-1 -yl)-1,2,4-oksadiazol-3 -yl]syklopropyl]benzensulfonamid
- 15 4-[*trans*-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]-3-metylbenzensulfonamid
- 4-[(1*R*,3*R*)-3-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl] benzensulfonamid;
- 4-[(1*R*,3*R*)-3-{3-[4-Fluor-2-(trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 20 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-{3-[5-Klor-2-(propan-2-yloxy)fenyl]-1,2,4-oksadiazol-5-yl}-2,2-dimetylsyklopropyl] benzensulfonamid;
- 25 4-[(1*S*,2*S*)-2-(3-Fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-[3-(5-Fluor-2-metylfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl] benzensulfonamid;
- 4-[(1*R*,3*R*)-3-[3-(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl] benzensulfonamid;
- 30 4-[(1*S*,2*S*)-2-[3-(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Difluor-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 4- [(1*R*,3*R*)-3-[3-(3 -Fluorfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl] benzensulfonamid;
- 35

- 4- $\{(1R,3R)$ -3-[3-(2,6-Difluorfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4- $\{(1R,3R)$ -3- [3 -(2-Fluorfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 5 4- $[(1R,3R)$ -2,2-Dimetyl-3- {3 - [2-(trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}syklopropyl] benzensulfonamid;
- 4- $\{(1R,3R)$ -3-[3-(3-Bromofenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4- $\{(1S,2S)$ -2-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl] syklopropyl } benzensulfonamid;
- 10 4- $\{(1R,3R)$ -2,2-Dimetyl-3-[3-(propan-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4- $\{(1R,3R)$ -3-[3-(5-Fluorpyridin-3-yl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 15 4- $[(1R,3R)$ -3-(3-Syklobutyl-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4- $[(1S,2S)$ -2-(3-Sykloheksyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 4- $\{(1S,2S)$ -2-[3-(5-Fluorpyridin-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 20 4- $\{(1S,2S)$ -2-[3-(2-Metylpyridin-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4- $[(1R,3R)$ -2,2-Dimetyl-3-{3-[5-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl] benzensulfonamid;
- 25 4- $\{(1R,3R)$ -3-[3-(3,3-Difluorsyklobutyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4- $[(1R,3R)$ -3-(3-Syklopentyl-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4- $\{(1R,3R)$ -3-[3-(Syklopropylmetyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 30 4- $\{(1R,3R)$ -2,2-Dimetyl-3-[3-(tetrahydrofuran-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4- $\{(1R,3R)$ -2,2-Dimetyl-3-[3-(tetrahydrofuran-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 35 4- $\{(1R,3R)$ -2,2-Dimetyl-3-[3 -(1-fenylsyklopropyl)-1,2,4-oksadiazol-5-yl] syklopropyl} benzensulfonamid;

- 4- $\{(1R,3R)$ -3-[3-(5-Fluor-2,3-dihydro-1*H*-inden-1-yl)-1,2,4-oksadiazol-5-yl]-2,2-dimetyl syklopropyl}benzensulfonamid;
- 4- $\{(1R,3R)$ -2,2-Dimetyl-3-[3 -(spiro[3.3]hept-2-yl)-1,2,4-oksadiazol-5-yl] syklopropyl} benzensulfonamid;
- 5 4- $\{(1R,3R)$ -3-[3-(1-Acetylpiperidin-4-yl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(3-*tert*-Butyl-1,2,4-oksadiazol-5-yl)-2,2-difluorsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{3-[1-(trifluormetyl)syklopropyl]-1,2,4-oksadiazol-5-yl} syklopropyl]benzensulfonamid;
- 10 4-[(1*S*,3*S*)-3-(3-Syklopentyl-1,2,4-oksadiazol-5-yl)-2,2-difluorsyklopropyl]benzensulfonamid;
- 4- $\{(1S,3S)$ -3-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 15 4-[(1*S*,3*S*)-3-{3-[4-Fluor-2-(trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}-2,2-dimetyl syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-{3-[5-Klor-2-(propan-2-yloxy)fenyl]-1,2,4-oksadiazol-5-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 20 4-[(1*R*,2*R*)-2-(3-Fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-{3-[2-(Trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}syklopropyl] benzensulfonamid;
- 4-[(1*R*,2*R*)-2-{3-[4-Fluor-2-(trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}syklopropyl] benzensulfonamid;
- 25 4-[(1*R*,2*R*)-2-{3-[5-Fluor-2-(trifluormetyl)fenyl]-1,2,4-oksadiazol-5-yl}syklopropyl] benzensulfonamid;
- 4- $\{(1R,2R)$ -2-[3 -(2,6-Difluorfenyl)-1,2,4-oksadiazol-5-yl] syklopropyl}benzensulfonamid;
- 4- $\{(1R,2R)$ -2-[3-(3-Bromofenyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 30 4- $\{(1R,2R)$ -2-[3-(2-Fluor-6-metylfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4- $\{(1S,3S)$ -3-[3-(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 35

- 4- {(1*R*,2*R*)-2-[3-(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl}
benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(4-Fluorfenyl)-1,2,4-oksadiazol-5-
yl]syklopropyl}benzensulfonamid;
- 5 4- {(1*R*,2*R*)-2-[3-(2,3-Difluorfenyl)-1,2,4-oksadiazol-5-yl]
syklopropyl}benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(2,5-Difluorfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl}
benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(2-Metylfenyl)-1,2,4-oksadiazol-5-
yl]syklopropyl}benzensulfonamid;
- 10 4- {(1*R*,2*R*)-2-[3-(3-Metylfenyl)-1,2,4-oksadiazol-5-
yl]syklopropyl}benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(4-Metylfenyl)-1,2,4-oksadiazol-5-
yl]syklopropyl}benzensulfonamid;
- 15 4- {(1*R*,2*R*)-2-[3-(2-Fluorfenyl)-1,2,4-oksadiazol-5-
yl]syklopropyl}benzensulfonamid;
- 4- [(1*R*,3*R*)-2,2-Difluor-3-(3-fenyl-1,2,4-oksadiazol-5-
yl)syklopropyl]benzensulfonamid;
- 4- {(1*R*,3*R*)-2,2-Difluor-3-[3-(propan-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}
benzensulfonamid;
- 20 4- [(1*S*,3*S*)-2,2-Dimetyl-3-{3-[4-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-
yl} syklopropyl]benzensulfonamid;
- 4- [(1*S*,3*S*)-3-(3-Sykloheksyl-1,2,4-oksadiazol-5-yl)-2,2-
dimetylsyklopropyl]benzensulfonamid;
- 25 4- {(1*S*,3*S*)-2,2-Dimetyl-3-[3-(pyridin-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}
benzensulfonamid;
- 4- {(1*S*,3*S*)-2,2-Dimetyl-3-[3-(propan-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}
benzensulfonamid;
- 4- {(1*S*,3*S*)-3-[3-(5-Fluorpyridin-3-yl)-1,2,4-oksadiazol-5-yl]-2,2-
dimetylsyklopropyl} benzensulfonamid;
- 30 4- [(1*S*,3*S*)-3-(3-Syklobutyl-1,2,4-oksadiazol-5-yl)-2,2-
dimetylsyklopropyl]benzensulfonamid;
- 4- [(1*R*,2*R*)-2-(3-Sykloheksyl-1,2,4-oksadiazol-5-
yl)syklopropyl]benzensulfonamid;
- 35 4- [(1*S*,3*S*)-3-(3-Syklopropyl-1,2,4-oksadiazol-5-yl)-2,2-
dimetylsyklopropyl]benzensulfonamid;

- 4-[(1*S*,3*S*)-3-(3-*tert*-Butyl-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(Propan-2-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 5 4-{(1*R*,2*R*)-2-[3-(5-Fluorpyridin-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(3-metyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
- 10 4-{(1*S*,3*S*)-2,2-Dimetyl-3-[3-(2,2,2-trifluoretyl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4-{(1*S*,3*S*)-2,2-Dimetyl-3-[3-(2-metylpyridin-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 4-{(1*R*,2*R*)-2-[3 -(2-Metylpyridin-3 -yl) -1,2,4-oksadiazol-5-yl] syklopropyl}benzensulfonamid;
- 15 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{3-[5-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl] benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[3-(3,3-Difluorsyklobutyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(3,3 -Difluorsyklobutyl)-1,2,4-oksadiazol-5 -yl] syklopropyl}benzensulfonamid;
- 20 4-[(1*S*,3*S*)-3-(3-Syklopentyl-1,2,4-oksadiazol-5-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(3-Syklopentyl-1,2,4-oksadiazol-5 -yl) syklopropyl] benzensulfonamid;
- 25 4-[(1*R*,2*R*)-2-{3-[5-(Trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl] benzensulfonamid;
- 4-{(1*R*,2*R*)-2-[3-(1-Fenylsyklopropyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4-{(1*R*,2*R*)-2-[3-(2-Syklopropylpyridin-3-yl)-1,2,4-oksadiazol-5-yl]syklopropyl} benzensulfonamid;
- 30 4-[(1*R*,2*R*)-2-{3-[4-(Trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl] benzensulfonamid;
- 4-{(1*R*,2*R*)-2-[3-(2,4-Difluorbenzyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 35 4-{(1*S*,3*S*)-3-[3-(Syklopropylmetyl)-1,2,4-oksadiazol-5-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;

- 4- {(1*R*,2*R*)-2-[3-(Syklopropylmetyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{3-[6-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl]benzensulfonamid;
- 5 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{3-[2-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-5-yl} syklopropyl] benzensulfonamid;
- 4- {(1*R*,2*R*)-2-[3-(4-Metyl-1,3-oksazol-5 -yl)-1,2,4-oksadiazol-5 -yl] syklopropyl} benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[3-(2-Hydroksysykloheksyl)-1,2,4-oksadiazol-5-yl]-2,2-
- 10 dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{3-[1-(trifluormetyl)syklopropyl]-1,2,4-oksadiazol-5-yl} syklopropyl]benzensulfonamid;
- 4-{(1*S*,3*S*)-2,2-Dimetyl-3-[3-(1-metylsykloheksyl)-1,2,4-oksadiazol-5-yl] syklopropyl}benzensulfonamid;
- 15 4- {(1*R*,3*R*)-2,2-Difluor-3-[3-(2-fluorpropan-2-yl)-1,2,4-oksadiazol-5-yl] syklopropyl } benzensulfonamid;
- 4-{*trans*-2-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl]syklopropyl}benzensulfonamid;
- 4-{*trans*-3-[3-(5-Klor-2-metoksyfenyl)-1,2,4-oksadiazol-5-yl]-2,2-
- 20 difluorsyklopropyl} benzensulfonamid;
- 4- {2-[3 -(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]-2-metylsyklopropyl} benzensulfonamid;
- 4-{2-[3-(2,4-Difluorfenyl)-1,2,4-oksadiazol-5-yl]-1-metylsyklopropyl}benzensulfonamid;
- 25 4- {(1*R*,3*R*)-3 - [5-(2,6-Difluorfenyl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*R*,3*R*)-3-{5-[5-Fluor-2-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl}-2,2-dimetyl syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-{5-[2-Fluor-6-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl} -2,2-
- 30 dimetylsyklopropyl] benzensulfonamid;
- 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(5-fenyl-1,3,4-tiadiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(5-fenyl-1*H*-1,2,4-triazol-3-yl)syklopropyl]benzensulfonamid;
- 35 4-{(1*R*,3*R*)-3-[5-(2-Syklopropylpyridin-3-yl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;

- 4-[(1*R*,3*R*)-3-(5-Sykloheksyl-1,3,4-tiadiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(5-fenyl-1,3,4-oksadiazol-2-yl)syklopropyl]benzensulfonamid;
- 5 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{5-[3-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl}syklopropyl] benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[5-(3-Fluorfenyl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-{5-[2-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl} syklopropyl] benzensulfonamid;
- 10 4-{(1*S*,3*S*)-3-[5-(2,6-Difluorfenyl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-3-{5-[5-Fluor-2-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 15 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(5-fenyl-1,3,4-tiadiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[5-(2,4-Difluorfenyl)-1,3,4-tiadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1*S*,3*S*)-2,2-Dimetyl-3-[5-(propan-2-yl)-1,3,4-oksadiazol-2-yl]syklopropyl} benzensulfonamid;
- 20 4-[(1*S*,3*S*)-3-(5-Syklopentyl-1,3,4-oksadiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[5-(Syklopropylmetyl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 25 4-{(1*S*,3*S*)-3-[5-(2-Syklopropylpyridin-3-yl)-1,3,4-oksadiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(5-Sykloheksyl-1,3,4-tiadiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(5-Syklopentyl-1,3,4-tiadiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 30 4-[(1*S*,3*S*)-3-(5-Syklopropyl-1,3,4-tiadiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(5-Syklopentyl-1,3,4-tiadiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-{5-[2-Fluor-6-(trifluormetyl)fenyl]-1,3,4-oksadiazol-2-yl} -2,2-dimetyl syklopropyl] benzensulfonamid;
- 35

- 4-[(1S,3S)-2,2-Dimetyl-3-(5-fenyl-1,2,4-oksadiazol-3-yl)syklopropyl]benzensulfonamid;
- 4-{(1S,3S)-3-[5-(2-Klor-4-fluorfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 5 4-{(1S,3S)-2,2-Dimetyl-3-[5-(2,4,6-trifluorfenyl)-1,2,4-oksadiazol-3-yl)syklopropyl} benzensulfonamid;
- 4-[(1S,3S)-3-{5-[4-Fluor-3-(trifluormetoksy)fenyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 4-{(1S,3S)-3-[5-(3-Fluorfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 10 4-{(1S,3S)-3-[5-(2-Fluor-6-metylfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1S,3S)-3-{5-[2-Fluor-5-(2-okso-1,3-oksazolidin-3-yl)fenyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetylsyklopropyl]benzensulfonamid;
- 15 4-{(1S,3S)-3-[5-(2,6-Difluorfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1S,3S)-3-[5-(3-Syklopropylfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1S,3S)-2,2-Dimetyl-3-[5-(2,3,5-trifluorfenyl)-1,2,4-oksadiazol-3-yl)syklopropyl} benzensulfonamid;
- 20 4-{(1S,3S)-3-[5-(4-Etynylfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1S,3S)-3-[5-(4-Cyanofenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 25 4-[(1S,3S)-2,2-Dimetyl-3-{5-[4-(trifluormetoksy)fenyl]-1,2,4-oksadiazol-3-yl}siklopropyl] benzensulfonamid;
- 4-[(1S,3S)-2,2-Dimetyl-3-{5-[3-(1,1,2,2-tetrafluoretoksy)fenyl]-1,2,4-oksadiazol-3-yl} syklopropyl]benzensulfonamid;;
- 4-{(1R,2R)-2-[5-(3-Fluorfenyl)-1,2,4-oksadiazol-3-yl)syklopropyl}benzensulfonamid;
- 30 4-{(1S,3S)-3-[5-(2,4-Difluorbenzyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1S,3S)-3-{5-[1-(3-Klorphenoxy)etyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetylsyklopropyl] benzensulfonamid;
- 35 4-{(1S,3S)-3-[5-(5-Fluor-2,3-dihydro-1*H*-inden-1-yl)-1,2,4-oksadiazol-3-yl]-2,2-dimetyl syklopropyl}benzensulfonamid;

- 4-[(1S,3S)-3-{5-[1-(2,5-Difluorfenyl)syklobutyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 4-[(1S,3S)-3-{5-[(5-Klor-2-okso-1,3-benzoksazol-3-(2H)-yl)metyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetylsyklopropyl]benzensulfonamid;
- 5 4-{(1S,3S)-2,2-Dimetyl-3-[5-(1,3-tiazol-4-yl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 4-{(1S,3S)-2,2-Dimetyl-3-[5-(4-metyl-1,3-oksazol-5-yl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 4-{(1S,3S)-3-[5-(2-Syklopropyl-1H-imidazol-4-yl)-1,2,4-oksadiazol-3-yl]-2,2-dimetyl syklopropyl}benzensulfonamid;
- 10 4-{(1S,3S)-3-[5-(1-Syklopropylpiperidin-4-yl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1S,3S)-2,2-Dimetyl-3-[5-(1-metyl-1H-pyrrol-3-yl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 15 4-[(1S,3S)-3-{5-[1-(1H-Imidazol-1-yl)etyl]-1,2,4-oksadiazol-3-yl}-2,2-dimetylsyklopropyl] benzensulfonamid;
- 4-[(1S,3S)-2,2-Dimetyl-3-{5-[1-(pyrazin-2-yl)syklopropyl]-1,2,4-oksadiazol-3-yl} syklopropyl] benzensulfonamid;
- 4-[(1S,3S)-2,2-Dimetyl-3-{5-[4-(trifluormetyl)kinolin-2-yl]-1,2,4-oksadiazol-3-yl} syklopropyl] benzensulfonamid;
- 20 4-[(1S,3S)-3-{5-[6-(2-Fluoretoksy)pyridin-3-yl]-1,2,4-oksadiazol-3-yl}-2,2-dimetyl syklopropyl]benzensulfonamid;
- 4-{(1S,3S)-2,2-Dimetyl-3-[5-(tetrahydrofuran-2-ylmetyl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 25 4-{(1S,3S)-3-[5-(1,1-Difluoretyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1S,3S)-3-{5-[4-(4-Fluorfenyl)-1H-imidazol-2-yl]-1,2,4-oksadiazol-3-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 4-[(1S,3S)-2,2-Dimetyl-3-(5-{2-[(2,2,2-trifluoretyl)sulfanyl]-1,3-oksazol-5-yl}-1,2,4-oksadiazol-3-yl)syklopropyl]benzensulfonamid;
- 30 4-[(1S,3S)-2,2-Dimetyl-3-{5-[3-(trifluormetyl)pyridin-4-yl]-1,2,4-oksadiazol-3-yl} syklopropyl] benzensulfonamid;
- 4-[(1S,3S)-2,2-Dimetyl-3-{5-[4-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-3-yl} syklopropyl]benzensulfonamid;
- 35 4-[(1S,3S)-2,2-Dimetyl-3-{5-[2-(trifluormetyl)pyridin-3-yl]-1,2,4-oksadiazol-3-yl} syklopropyl] benzensulfonamid;


- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-[5-(4*H*-tieno[3,2-*b*]pyrrol-5-yl)-1,2,4-oksadiazol-3-yl]syklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-3-{5-[1-(Syklopropylkarbonyl)azetidin-3-yl]-1,2,4-oksadiazol-3-yl}-2,2-dimetyl syklopropyl] benzensulfonamid;
- 5 4-[(1*S*,3*S*)-3-[5-(2-Syklopentyl-1-oksooktahydrosyklopenta[*c*]pyrrol-5-yl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(5-Syklopropyl-1,2,4-oksadiazol-3-yl)-2,2-dimetylsyklopropyl] benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(5-Syklopentyl-1,2,4-oksadiazol-3-yl)-2,2-
- 10 dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-[5-(spiro[2.5]oct-4-yl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-[5-(2,2,2-trifluor-1-hidroksyetyl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
- 15 4-[(1*S*,3*S*)-3-[5-(4-Hidroksysykloheksyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-3-[5-(3-Hidroksysyklobutyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-[5-(3-okso-3,4-dihydro-2*H*-1,4-benzoksazin-8-yl)-1,2,4-oksadiazol-3-yl] syklopropyl}benzensulfonamid;
- 20 4-[(1*S*,3*S*)-3-[5-(2-Hidroksy-1,3-benzotiazol-6-yl)-1,2,4-oksadiazol-3-yl]-2,2-dimetyl syklopropyl}benzensulfonamid;
- 4-[(1*R*,3*R*)-3-[5-(2-Syklopropyletyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 25 4-[(1*R*,2*R*)-2-(5-Sykloheksyl-1,2,4-oksadiazol-3-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-{5-[1-(Trifluormetyl)syklopropyl]-1,2,4-oksadiazol-3-yl}syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-[5-(5-Fluorpyridin-3-yl)-1,2,4-oksadiazol-3-
- 30 yl]syklopropyl}benzensulfonamid;
- 4-[(1*R*,3*R*)-3-[4-(2-Fluorfenyl)-1,3-oksazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4- [(1*R*,3*R*)-3- [4-(2,4-Difluorfenyl)-1 ,3 -oksazol-2-yl] -2,2-dimetylsyklopropyl} benzensulfonamid;
- 35 4- [(1*R*,3*R*)-3- [4-(2,5-Difluorfenyl)-1,3 -oksazol-2-yl] -2,2-dimetylsyklopropyl} benzensulfonamid;

- 4-[(1*R*,3*R*)-3-(4-*tert*-Butyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(4-Syklopropyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 5 4-[(1*S*,2*S*)-2-(4-Fenyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 4-{(1*S*,2*S*)-2-[4-(3-Fluorfenyl)-1,3-tiazol-2-yl]syklopropyl} benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(4-Syklopentyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(5-Syklopentyl-1,3-tiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 10 4-{(1*S*,2*S*)-2-[5-(3-Fluorfenyl)-1,3-tiazol-2-yl]syklopropyl} benzensulfonamid;
- 4-[1*S*,3*S*)-3-(5-Syklopentyl-1,3-oksazol-2-yl)-2,2-difluorsyklopropyl]benzensulfonamid; 4-{(1*S*,3*S*)-3-[4-(2-Fluorfenyl)-1,3-oksazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 15 4-{(1*S*,3*S*)-3-[4-(2,5-Difluorfenyl)-1,3-oksazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[4-(2,4-Difluorfenyl)-1,3-oksazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(5-*tert*-Butyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 20 4-[(1*R*,2*R*)-2-(5-Syklopropyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(4-Etyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(4-*tert*-Butyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(4-Etyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 25 4-[(1*R*,2*R*)-2-(4-Fenyl-1,3-tiazol-2-yl)syklopropyl]benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[4-(3-Fluorfenyl)-1,3-tiazol-2-yl]-2,2-dimetylsyklopropyl} benzensulfonamid;
- 4-{(1*S*,3*S*)-2,2-Dimetyl-3-[4-(propan-2-yl)-1,3-tiazol-2-yl]syklopropyl}benzensulfonamid;
- 30 4-[(1*R*,2*R*)-2-(4-Fenyl-1*H*-imidazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(5-Syklopentyl-1,3-oksazol-2-yl)-2,2-difluorsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(5-Syklopentyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 35 4-[(1*R*,2*R*)-2-(5-Syklopentyl-1,3-tiazol-2-yl)syklopropyl]benzensulfonamid;

- 4-[(1*S*,3*S*)-3-(5-Syklopentyl-1,3-tiazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(4-Syklopentyl-1,3-oksazol-2-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 5 4-{(1*R*,2*R*)-2-[5-(3-Fluorfenyl)-1,3-tiazol-2-yl]syklopropyl}benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(4-Syklopentyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,3*S*)-3-(4-Sykloheksyl-1,3-tiazol-2-yl)-2,2-difluorsyklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(2-fenyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
- 10 4-[(1*S*,2*S*)-2-(2-Fenyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*R*,2*R*)-2-(2-Fenyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(3-fenylisoksazol-5-yl)syklopropyl]benzensulfonamid;
- 4- {(1*R*,3*R*)-3- [1 -(3-Fluorfenyl)-1*H*-1,2,3-triazol-4-yl]-2,2-dimetylsyklopropyl}
- 15 benzensulfonamid;
- 4-{(1*S*,3*S*)-3-[1-(3-Fluorfenyl)-1*H*-1,2,3-triazol-4-yl]-2,2-dimetylsyklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Dimetyl-3-(1-fenyl-1*H*-1,2,3-triazol-4-yl)syklopropyl]benzensulfonamid;
- 20 4-[(1*R*,3*R*)-3-(1-Syklopentyl-1*H*-pyrazol-4-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(5-Etoksy-1,2,4-tiadiazol-3-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-{(1*R*,2*R*)-2-[5-(3-Fluorfenyl)-1,2,4-tiadiazol-3-yl]syklopropyl}benzensulfonamid;
- 25 4-[(1*R*,2*R*)-2-(5-Sykloheksyl-1,2,4-tiadiazol-3-yl)syklopropyl]benzensulfonamid;
- 4-{(1*S*,3*S*)-2,2-Difluor-3-[5-(piperidin-1-yl)-1,2,4-tiadiazol-3-yl]syklopropyl}benzensulfonamid;
- 4-[(1*S*,3*S*)-2,2-Difluor-3-(5-fenyl-1,2,4-tiadiazol-3-yl)syklopropyl]benzensulfonamid;
- 30 4-[(1*R*,2*R*)-2-(2-Syklopentyl-1,3-tiazol-4-yl)syklopropyl]benzensulfonamid;
- 4-[(1*S*,3*S*)-3-(2-Syklopentyl-1,3-tiazol-4-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 4-[(1*R*,3*R*)-3-(5-Sykloheksyl-1,2,4-oksadiazol-3-yl)-2,2-dimetylsyklopropyl]benzensulfonamid;
- 35


- 4-[(1*R*,3*R*)-2,2-Dimetyl-3-(5-fenyl-1,2,4-oksadiazol-3-yl)syklopropyl]benzensulfonamid;
 4-{(1*R*,3*R*)-3-[5-(3-Fluorfenyl)-1,2,4-oksadiazol-3-yl]-2,2-dimetylsyklopropyl}benzensulfonamid;
 5 4-[(1*R*,3*R*)-2,2-Dimetyl-3-{5-[1-(trifluormetyl)syklopropyl]-1,2,4-oksadiazol-3-yl} syklopropyl]benzensulfonamid;
 4-{(1*R*,3*R*)-2,2-Dimetyl-3-[5-(piperidin-1-yl)-1,2,4-oksadiazol-3-yl]syklopropyl} benzensulfonamid;
 4-[(1*R*,2*R*)-2-(2-Syklopentyl-1,3-oksazol-5-yl)syklopropyl]benzensulfonamid;
 10 4-[(1*S*,2*S*)-2-(2-Fenyl-1,3-tiazol-5-yl)syklopropyl]benzensulfonamid;
 4-[*trans*-2,2-Difluor-3-(5-fenyl-1,3-oksazol-2-yl)syklopropyl]benzensulfonamid;
 4-[2-Metyl-3 -(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
 4-[*trans*-2-(3-Fenyl-1,2,4-oksadiazol-5-yl)spiro[2.4]hept-1-yl]benzensulfonamid;
 15 4-{*trans*-2-[3-(3-Fluorfenyl)-1,2,4-tiadiazol-5-yl]syklopropyl} benzensulfonamid;
 4-[*trans*-2,2-Diklor-3-(3-syklopentyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid;
 4-{*trans*-3-[5-(3-Fluorfenyl)isoksazol-3-yl]-2,2-dimetylsyklopropyl}benzensulfonamid;
 20 4-[*trans*-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]-3-fluorbenzensulfonamid;
 4-[*trans*-2,2-Dimetyl-3-(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]-2-metylbenzensulfonamid; og
 25 4-[*trans*-2,2-Diklor-3 -(3-fenyl-1,2,4-oksadiazol-5-yl)syklopropyl]benzensulfonamid; eller et farmasøytisk akseptabelt salt derav.

11. Forbindelse ifølge ethvert foregående krav, som er




3433234

21




5

12. Farmasøytisk akseptabelt salt av en forbindelse ifølge ethvert foregående krav, som er



10



15

13. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) en forbindelse ifølge et hvilket som helst av kravene 1-10 eller et farmasøytisk akseptabelt salt derav, eller en forbindelse ifølge krav 11 er et farmasøytisk akseptabelt salt ifølge krav 12.

20

3433234

22

14. Farmasøytisk sammensetning ifølge krav 13, videre omfattende et andre terapeutisk middel valgt fra gruppen bestående av acetylkolinsterase-hemmere; NMDA-reseptorantagonister; antipsykotika; MAO-B-hemmere; og levodopa.


5 15. Kombinasjon av en forbindelse eller et farmasøytisk akseptabelt salt derav ifølge et hvilket som helst av kravene 1-12, videre omfattende et andre terapeutisk middel valgt fra gruppen bestående av acetylkolinsterase-hemmere; NMDA-reseptorantagonister; antipsykotika; MAO-B-hemmere; og levodopa.

10 16. Forbindelse ifølge et hvilket som helst av kravene 1-10, eller et farmasøytisk akseptabelt salt derav, for bruk i terapi.

15 17. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for bruk i en fremgangsmåte ved behandling av en pasient med kognitive svekkelser knyttet til Alzheimers sykdom, Parkinsons sykdom og schizofreni.


20 18. Forbindelse ifølge krav 11 eller farmasøytisk akseptabelt salt derav ifølge krav 12, for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.

19. Forbindelse ifølge krav 1, som er




25

20. Forbindelse ifølge krav 1, som er




3433234

23



21. Forbindelse ifølge krav 20, som er det farmasøytisk akseptable saltet av

5



22. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 19.


10

23. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 20.

24. Forbindelse ifølge krav 19 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type,

15

25. Forbindelse ifølge krav 1, som er




20


26. Forbindelse ifølge krav 1 som er

3433234

24




eller et farmasøytisk akseptabelt salt av



5

27. Forbindelse ifølge krav 26, som er det farmasøytisk akseptable saltet av



10

28. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 25.


29. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 26.

15

30. Forbindelse ifølge krav 25 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.

20


31. Forbindelse ifølge krav 1, som er



3433234


25

32. Forbindelse ifølge krav 1, som er




5

eller et farmasøytisk akseptabelt salt av



33. Forbindelse ifølge krav 32, som er det farmasøytisk akseptable saltet av



10

34. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 31.

15

35. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 32.


36. Forbindelse ifølge krav 31 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.

20

37. Forbindelse ifølge krav 1, som er


3433234

26




38. Forbindelse ifølge krav 1, som er

5




eller et farmasøytisk akseptabelt salt av



10

39. Forbindelse ifølge krav 38, som er det farmasøytisk akseptable saltet av



15

40. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 37.

41. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 38.


20

42. Forbindelse ifølge krav 37 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.

3433234


27

43. Forbindelse ifølge krav 1, som er




5

44. Forbindelse ifølge krav 1, som er




10

eller et farmasøytisk akseptabelt salt av



45. Forbindelse ifølge krav 44, som er det farmasøytisk akseptable saltet av



15

46. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 43.

20

47. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 44.


3433234

28

48. Forbindelse ifølge krav 43 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.


49. Forbindelse ifølge krav 1, som er

5



50. Farmasøytisk akseptabelt salt av en forbindelse ifølge krav 1, som er

10



51. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) forbindelsen ifølge krav 49.

15

52. Farmasøytisk sammensetning omfattende (i) en farmasøytisk akseptabel bærer og (ii) det farmasøytisk akseptable saltet ifølge krav 50.

53. Forbindelse ifølge krav 49 for bruk i en fremgangsmåte ved behandling av en pasient med mild til moderat demens av Alzheimers type.

20